What are the recommended treatment options for psoriasis?

Treatment for Psoriasis

For moderate-to-severe psoriasis, biologic therapy is the most effective treatment option, with IL-23 inhibitors and IL-17 inhibitors providing the highest rates of complete skin clearance, while methotrexate or adalimumab remain appropriate first-line systemic options when cost or availability limit biologic access. 1

Treatment Algorithm by Disease Severity

Mild Psoriasis (<3% BSA)

• Topical corticosteroids (high-potency) combined with vitamin D analogues (calcipotriol/betamethasone combination formulations) are first-line 2
• Topical calcineurin inhibitors for facial and intertriginous areas to avoid skin atrophy 2
• Consider topical roflumilast or tapinarof as FDA-approved alternatives 3

Moderate-to-Severe Psoriasis (≥3% BSA or high-impact sites)

First-Line Systemic Options (Strength A recommendations):

1. Methotrexate 7.5-25 mg weekly (oral or subcutaneous) 4

   • Most cost-effective systemic option
   • Requires folic acid supplementation to reduce GI/hepatic adverse effects
   • Monitor liver function every 3-6 months
   • Critical contraindications: pregnancy, cirrhosis, significant cytopenias
   • Women must wait 3 months after discontinuation before pregnancy

2. TNF-α Inhibitors:

   • Adalimumab: 80 mg initial dose, then 40 mg weekly after 1 week, then 40 mg every 2 weeks 1
   • Etanercept: 50 mg twice weekly for 12 weeks, then 50 mg weekly maintenance 1
   • Infliximab: Requires infusion administration; higher immunogenicity risk 1

3. IL-12/23 Inhibitor - Ustekinumab:

   • ≤100 kg: 45 mg at weeks 0,4, then every 12 weeks 1
   • >100 kg: 90 mg at weeks 0,4, then every 12 weeks 1
   • PASI 75 rates: 67-76% at week 12 1

Higher Efficacy Options (for complete clearance):

1. IL-17 Inhibitors (secukinumab, brodalumab, ixekizumab) 1

   • Provide rapid and near-complete skin clearance 5
   • Caution: Monitor for mucocutaneous candidiasis and inflammatory bowel disease 5

2. IL-23p19 Inhibitors (guselkumab, risankizumab, tildrakizumab) 1

   • Most durable treatment responses with longest dosing intervals 5
   • Highest rates of complete clearance among biologics 5

Special Considerations

Psoriatic Arthritis

• Methotrexate is effective for peripheral arthritis but NOT axial involvement 4
• TNF inhibitors (adalimumab, etanercept, infliximab) are superior to methotrexate for joint disease 4
• Ustekinumab is recommended for any severity psoriasis with psoriatic arthritis 1

High-Impact Sites

Nail Psoriasis:

• Adalimumab (Strength A) 1
• Ustekinumab (Strength B) - 100% improvement by week 40 1

Scalp Psoriasis:

• Etanercept (Strength A) 1
• Adalimumab (Strength B) 1

Palmoplantar Psoriasis:

• Adalimumab (Strength A) 1
• Ustekinumab (Strength B) - 67% clearance with 90 mg dose 1

Combination Therapy to Augment Efficacy

Evidence-based combinations (all Strength B recommendations):

• Any biologic + high-potency topical corticosteroids with/without vitamin D analogue 1
• Methotrexate + narrowband UVB phototherapy 4
• Biologics + methotrexate 1
• Biologics + narrowband UVB phototherapy 1

Comparative Efficacy

Methotrexate is less effective than adalimumab and infliximab for cutaneous psoriasis (Strength A) 4. However, it remains a recommended first-line option when biologics are not accessible due to cost or availability 6.

The most recent French guidelines (2025) recommend methotrexate, adalimumab, or ustekinumab as primary systemic treatment for patients without symptomatic comorbidities 6.

Critical Monitoring Requirements

Methotrexate

• Baseline: CBC, liver function, hepatitis B/C, kidney function, pregnancy test 4
• Ongoing: Liver function every 3-6 months 4
• Annual GI/hepatology referral or transient elastography if baseline liver abnormalities 4
• Avoid moderate alcohol use (>1 drink/day for women, >2 drinks/day for men) 4

Biologics

• Baseline: TB screening, hepatitis B/C, CBC 1
• Monitor for infections, infusion reactions (infliximab), injection site reactions 1

Common Pitfalls

1. Infliximab intervals >8 weeks increase immunogenicity risk and infusion reactions 1
2. High-dose folic acid may reduce methotrexate efficacy - use appropriate supplementation only 4
3. Methotrexate test dose recommended in patients with impaired kidney function 4
4. IL-17 inhibitors contraindicated in active inflammatory bowel disease 5